Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies

Pharmacogenetics

Volumn 12, Issue 8, 2002, Pages 605-611

  Blanco, Javier G ^a   Edick, Mathew J ^a   Hancock, Michael L ^a   Winick, Naomi J ^d   Dervieux, Thierry ^a   Amylon, Michael D ^e   Bash, Robert O ^f   Behm, Frederick G ^a   Camitta, Bruce M ^g   Pui, Ching Hon ^a,c   Raimondi, Susana C ^a   Relling, Mary V ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f CHILDREN S MEDICAL CENTER   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Children; Therapy related leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOSINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THIAMINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROMOTER REGION; RACE;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOID; MALE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC;

PIERINAE;

EID: 12244252803     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200211000-00004     Document Type: Article

References (36)

1. Pui C H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339:605-615.
2. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325:1682-1687.
3. Winick N J, Smith SD, Shuster J, Lauer S, Wharam MD, Land V, et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1993; 11:271-278.
4. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002; 99:1909-1912.
5. Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000; 109:13-23.
6. Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol 1999; 36:59-72.
7. Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 1992; 261:491-496.
8. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4 Mol Pharmacol 1994; 45:352-358.
9. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12:346-352.
10. Lovett BD, Strumberg D, Blair IA, Pang S, Burden DA, Megonigal MD, et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 2001; 40:1159-1170.
11. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung N-KV, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95:13176-13181.
12. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999; 259:201-205.
13. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66:288-294.
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
15. Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 1994; 6:493-500.
16. Joseph P, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA 1994; 91:8413-8417.
17. Joseph P, Long DJ, Klein-Szanto AJ, Jaiswal AK. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem Pharmacol 2000; 60:207-214.
18. Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau MM, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94:803-807.
19. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6:4091-4095.
20. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 1999; 59:4095-4099.
21. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000; 14:2276-2285.
22. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14:2286-2294.
23. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337:61-66.
24. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338:499-505.
25. Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9:1680-1684.
26. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 1999; 13:335-342.
27. Laver JH, Barredo JC, Amylon M, Schwenn M, Kurtzberg J, Camitta BM, et al. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: A Pediatric Oncology Group report. Leukemia 2000; 14:369-373.
28. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-1229.
29. Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, Camitta B, et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 2000; 14:232-237.
30. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999; 9:113-121.
31. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
32. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 2001; 1:99-108.
33. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67:48-56.
34. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997; 76:852-854.
35. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-132.
36. Rothman N, Smith MT, Hayes RB, Traver RD, Hoener B, Campleman S, et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997; 57:2839-2842.